Effects of Oral Alendronate on BMD in Adult Patients With Osteogenesis Imperfecta: A 3‐Year Randomized Placebo‐Controlled Trial

@article{Chevrel2006EffectsOO,
  title={Effects of Oral Alendronate on BMD in Adult Patients With Osteogenesis Imperfecta: A 3‐Year Randomized Placebo‐Controlled Trial},
  author={Guillaume Chevrel and Anne-Marie Schott and Elisabeth Fontanges and J. E. Charrin and Genevi{\'e}ve Lina-Granade and François Duboeuf and Patrick Garnero and Monique E. Arlot and C Raynal and Pierre Jean Meunier},
  journal={Journal of Bone and Mineral Research},
  year={2006},
  volume={21}
}
A 3‐year, randomized, double‐blind, placebo‐controlled trial evaluated the effect of oral alendronate on the BMD of 64 adult patients with osteogenesis imperfecta. The mean increases in the lumbar spine BMD were 10.1 ± 9.8% (p < 0.001) and 0.7 ± 5.7% in the alendronate and placebo groups, respectively. Oral alendronate increases BMD in adult patients with osteogenesis imperfecta. 
Oral Bisphosphonate Therapy for Osteogenesis Imperfecta: A Systematic Review and Meta‐Analysis of Six Randomized Placebo‐Controlled Trials
To assess the effectiveness and safety of oral bisphosphonates in increasing bone mineral density (BMD), reducing fractures, and improving clinical function in patients with osteogenesis imperfectaExpand
Evaluation of teriparatide treatment in adults with osteogenesis imperfecta.
TLDR
Osteoporosis Imperfecta patients with OI, particularly those with less severe disease (type I), displayed a teriparatide-induced anabolic response, as well as increased hip and spine aBMD, vertebral v BMD, and estimated vertebral strength. Expand
Bisphosphonates for the Prevention of Fractures in Osteogenesis Imperfecta: Meta‐Analysis of Placebo‐Controlled Trials
TLDR
The effects of bisphosphonates on fracture prevention in osteogenesis imperfecta are inconclusive and adequately powered trials with a fracture endpoint are needed to further investigate the risks and benefits of bis phosphonate in this condition. Expand
Long-term Effects of Neridronate in Adults with Osteogenesis Imperfecta: An Observational Three-Year Italian Study
TLDR
Long-term treatment with i.v. neridronate has positive effects on BMD and bone turnover markers with a good safety profile, although no significant effect on the risk of fracture was observed. Expand
Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up
  • Isabel Pavón de Paz, José Antonio Rosado Sierra, Carmen Pérez Blanco, Naiara Modroño Móstoles, Guadalupe Guijarro de Armas, Cristina Navea Aguilera
  • Medicine
  • Endocrinología, Diabetes y Nutrición (English ed.)
  • 2019
TLDR
Zoledronic acid is a convenient, safe, and effective treatment that increases BMD in adult patients with OI and the safety of this treatment is confirmed. Expand
THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
  • Xiao-jie Xu, D. Ma, +8 authors Mei Li
  • Medicine
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2016
TLDR
Oral ALN and intravenous ZOL are equally effective at increasing BMD and inhibiting bone turnover in adults with OI, and the treatment may reduce fractures in this study. Expand
Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study.
  • P. T. Leali, M. Balsano, +6 authors C. Doria
  • Medicine
  • Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases
  • 2017
TLDR
The results of this study showed a promising role of teriparatide in the therapy of OI type I and Neridronate appears to increase Bone Mineral Density (BMD) in adults with OI and reduces bone resorption by inhibition of osteoclastic activity. Expand
Bone Mineral Density and Fracture Rate in Response to Intravenous and Oral Bisphosphonates in Adult Osteogenesis Imperfecta
TLDR
A need to consider whether bisphosphonate treatment is appropriate for all adults with OI is appropriate, and results underscore a need for further research into this issue. Expand
Efficacy of Bisphosphonates on Bone Mineral Density and Fracture Rate in Patients With Osteogenesis Imperfecta: A Systematic Review and Meta-analysis
TLDR
This study showed that bisphosphonates could increase the BMD and reduce the risk of facture in patients with OI and there was no enough evidence to identify any differences in efficacy between oral and intravenous bisph phosphonates on fracture reduction, as well as between children and adults. Expand
Osteogenesis imperfecta: New treatment options
TLDR
A new approach has been developed to replace mutated genes using mesenchymal stem cells and a construct, which inactivates COL1A1, which may have an effect on the fracture rate in children and adult patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study
TLDR
Oral treatment with olpadronate at a daily dose of 10 mg/m2 results in a reduction of fracture risk of long bones in children with osteogenesis imperfecta, and the issue of whether bisphosphonates will alter the natural course of osteogenesisperfecta remains unresolved, and further studies are needed. Expand
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
TLDR
Two 48-week, randomized, placebo-controlled studies of two doses of alendronate in 477 men and women who were receiving glucocorticoid therapy found changes in bone density of the hip, biochemical markers of bone turnover, and the incidence of new vertebral fractures. Expand
Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta
TLDR
Disodium pamidronate (APD) was given as monthly intravenous infusions to 28 children and adolescents with severe OI or a milder form of the disease, but with spinal compression fractures to find an effective symptomatic treatment. Expand
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
TLDR
Alendronate increases bone density in patients receiving glucocorticoid therapy and there were no differences in serious adverse effects among the three groups, but there was a small increase in nonserious upper gastrointestinal effects in the group receiving 10 mg of alendronates. Expand
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
TLDR
Among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebra fractures, as well as other clinical fractures. Expand
Alendronate for the treatment of osteoporosis in men.
TLDR
In men with osteoporosis, alendronate significantly increases spine, hip, and total-body bone mineral density and helps prevent vertebral fractures and decreases in height. Expand
Long‐Term Effects of Bisphosphonates on the Growing Skeleton: Studies of Young Patients with Severe Osteoporosis
TLDR
It is necessary to select patients suitable for vaginal or laparoscopic mesh placement for PTH preoperatively on the basis of prior history and once they provide informed consent for surgery. Expand
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
TLDR
In children with severe osteogenesis imperfecta, cyclic administration of intravenous pamidronate improved clinical outcomes, reduced bone resorption, and increased bone density. Expand
Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.
TLDR
Reductions in fracture risk during treatment with alendronate are consistent in women with existing vertebral fractures and those without such fractures but with bone mineral density in the osteoporotic range. Expand
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
TLDR
Daily treatment with alendronate progressively increases the bone mass in the spine, hip, and total body and reduces the incidence of vertebral fractures, the progression of vertebra deformities, and height loss in postmenopausal women with osteoporosis. Expand
...
1
2
3
...